StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.67−0.98 (-6.69%)

Close on Nov 17, 2026Market cap $334.99MP/E –Yield –

Lyell Immunopharma total assets

Total assets on the balance sheet at the end of each period.

Lyell Immunopharma's total assets was $311.15M at Jun 30, 2026. For fiscal 2025 it was $340.05M, down 30.7% from the year before. The highest annual figure on record is $1.13B in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$340.05M-30.7%
FY2024Dec 31, 2024$490.86M-34.6%
FY2023Dec 31, 2023$750.03M-20.0%
FY2022Dec 31, 2022$937.56M-16.8%
FY2021Dec 31, 2021$1.13B+24.1%
FY2020Dec 31, 2020$908.28M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$311.15M-19.3%
Q1 FY2026Mar 31, 2026$350.63M-18.4%
Q4 FY2025Dec 31, 2025$340.05M-30.7%
Q3 FY2025Sep 30, 2025$407.97M-34.1%
Q2 FY2025Jun 30, 2025$385.45M-41.1%
Q1 FY2025Mar 31, 2025$429.80M-38.1%
Q4 FY2024Dec 31, 2024$490.86M-34.6%
Q3 FY2024Sep 30, 2024$619.22M-22.1%
Q2 FY2024Jun 30, 2024$654.14M-21.7%
Q1 FY2024Mar 31, 2024$694.22M-21.2%
Q4 FY2023Dec 31, 2023$750.03M-20.0%
Q3 FY2023Sep 30, 2023$794.99M-18.7%
Q2 FY2023Jun 30, 2023$835.35M-18.2%
Q1 FY2023Mar 31, 2023$880.45M-17.9%
Q4 FY2022Dec 31, 2022$937.56M-16.8%
Q3 FY2022Sep 30, 2022$977.27M-18.4%
Q2 FY2022Jun 30, 2022$1.02B-16.9%
Q1 FY2022Mar 31, 2022$1.07B+18.0%
Q4 FY2021Dec 31, 2021$1.13B–
Q3 FY2021Sep 30, 2021$1.20B–
Q2 FY2021Jun 30, 2021$1.23B–
Q4 FY2020Dec 31, 2020$908.28M–

More Lyell Immunopharma figures

See a number that looks wrong?